Proceeding of the company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals Limited held its 32nd Annual General Meeting on Tuesday, September 30, 2025, from 01:00 PM to 01:34 PM via video conferencing, chaired by Managing Director Mr. Dakshesh Shah. Four ordinary resolutions were transacted: adoption of the audited financial statements for FY ended March 31, 2025, approval and declaration of a final dividend for FY25, re-appointment of Mr. Dhruvin Shah (DIN: 08801693) as Executive Director (retiring by rotation), and appointment of a Secretarial Auditor for five consecutive years. The audit report contained no qualifications, reservations, or adverse remarks. Remote e-voting was conducted from September 27 to September 29, 2025, via NSDL, with Mrs. Rupal Patel appointed as Scrutinizer. No shareholders raised queries, and voting results are to be announced within 48 hours of the meeting's conclusion.
Routine procedural filing — the declaration of a final dividend and re-appointment of the Executive Director are mildly shareholder-friendly, but no material new information was disclosed. Investors should await the voting results and dividend amount, which will be disclosed separately within 48 hours.